Hepatitis C prevalence
— a nationwide serosurvey

Janaki Amin,1 Heather Gidding,2 Gwendolyn Gilbert,3 Josephine Backhouse,3 John Kaldor,1 Greg Dore,1
Margaret Burgess2

Abstract
Hepatitis C is the most commonly notified disease in Australia. In 1998 the Hepatitis C Virus Projections Working Group (HCPWG) estimated that there were approximately 210,000 people who had been infected by hepatitis C virus (HCV) in Australia by 2001. Population-based serosurveys are required to validate this estimate. Here we estimate HCV prevalence on the basis of HCV antibody seroprevalence in the Australian national serosurvey. Between 1996 and 1998, 2,800 sera opportunistically collected from pathology laboratories throughout Australia were tested for HCV antibody. National HCV notifications reported from 1991 through 1998 were also assessed. Eighty-one sera were HCV antibody positive, giving an age standardised prevalence of 2.3 per cent (95% CI 1.8%–2.9%). The 20–24 year age group had the highest HCV prevalence, 5.3 per cent (95%CI 3.3%–8.1%) and the male to female ratio was 1.8:1.0. Approximately 111,000 HCV notifications were received from 1991 through 1998. HCV prevalence estimated by the serosurvey is approximately three times higher than cumulative HCV notifications. Age and sex distributions of seroprevalence are broadly consistent with cumulative notification data. These distributions are consistent with the majority of HCV infections in Australia being transmitted by injecting drug use. Very low age specific seroprevalence estimates in the over 50 years age group indicate that there is not a large pool of undiagnosed infection in this age group. The serosurvey provides an estimate of Australian HCV prevalence and baseline data to determine incidence trends, both of which are required for health-care planning. Commun Dis Intell 2004;28:517–521.

Keywords: hepatitis C, prevalence, serosurvey

Introduction
Over the last decade hepatitis C (HCV) has been the most commonly notified infectious disease in Australia.1 The large population of people with HCV, together with estimates of continued high HCV incidence and the often long latency of HCV related disease, will produce an escalating health burden for at least the next two decades.2 The already increasing incidence of hepatocellular carcinoma is thought to be related to the expanding HCV epidemic and cirrhosis due to chronic HCV infection is already the most common underlying reason for liver transplantation.3,4 The true extent of this epidemic is however not known.

To date estimates of HCV prevalence and incidence have primarily relied on data from specific populations such as prison entrants, injecting drug users, blood product recipients, antenatal populations and blood donors.5–13 In 1998 the Hepatitis C Virus Projections Working Group (HCPWG) was formed with a brief to determine estimates of HCV incidence and prevalence in Australia. The HCPWG estimated that there were approximately 210,000 people who had been infected by HCV in Australian by 2001.2 This estimate was primarily derived from estimates of the prevalence of injecting drug use (IDU) and the incidence of HCV infection among IDUs. Population-based serosurveys are required to validate this estimate.
The first Australian national serosurvey of selected infectious diseases was conducted using sera collected in 1996–1998. Here we report the results for HCV antibody testing of specimens from the national serosurvey. We also compare the HCV seroprevalence estimates with the cumulative number of HCV notifications, to assess the potential extent of undiagnosed and unreported HCV infection in Australia.

Methods

Serosurvey

Details of the serosurvey are presented elsewhere. The samples were collected between July 1996 and December 1998. All major public and private diagnostic laboratories, including reference laboratories, throughout Australia were invited to contribute sera that had been submitted for diagnostic testing and would otherwise have been discarded. Forty-five of the 52 invited laboratories agreed to participate. Sera submitted to laboratories from sexual health clinics were excluded from this study.

All sera were tested by an indirect enzyme immunoassay (EIA), MONOLISA anti-HCV PLUS Version 2 (BIO-RAD, Marnes la Coquette, France) according to the manufacturer’s directions. Samples with an optical density (OD) below that of the cut-off less 10 per cent were deemed negative. All other samples were retested. On retesting, samples giving an OD less than the cut-off were reported as negative. Samples with an OD between that of the cut-off and the cut-off plus 10 per cent recorded as weak positive and all others as positive. The reactivity of samples in the latter two categories was confirmed by a strip immunoblot (using two encoded antigens and three encoded synthetic peptides), CHIRON* RIBA* HCV 3.0 SIA (Chiron Corporation, Emeryville, California, United States of America. Distributed by Ortho-Clinical Diagnostics, Incorporated, Raritan, New Jersey, United States of America) according to the manufacturer’s guidelines. The band patterns were interpreted as negative, indeterminate or positive for HCV infection. Indeterminate sera were subsequently assigned as negative for HCV infection.

Sample sizes were calculated for the following age groups: 1–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–39, 40–49, 50–59, 60–69 and 70+ years, based on the expected prevalence of hepatitis C antibodies. Within each age group, states and territories were sampled proportionally to their population size. Sample sizes were calculated to achieve confidence intervals of approximately +/-5 per cent for each age group. Approximately equal numbers of sera from males and females were tested. Australian Bureau of Statistics (ABS) end of 1997 population estimates were used to age standardise seroprevalence and to estimate the number of people exposed to HCV.

Notifications

Hepatitis C notification data (acute and unspecified) was extracted from the National Notifiable Diseases Surveillance System in August 2003 for cases with report date between 1 January 1991 and 31 December 1998 (Personal communication - Communicable Diseases Network Australia - National Notifiable Diseases Surveillance System, 2003). For comparison with the results of the serosurvey, the age distribution of cumulative notifications up to 1998 was determined by calculating age on the 1st of July 1998 based on date of birth or, if not available, the age at notification for each notification. Cumulative notification rates were calculated using the ABS end of 1997 population estimates.

Confidence intervals for HCV seroprevalence and cumulative notification rates by age group were calculated using exact binomial methods.

Ethics approval

The study was approved by appropriate institutional ethics committees and the State-wide Health Confidentiality and Ethics Committee of the New South Wales Health Department.

Results

Of the 2,800 sera tested, 81 were HCV antibody positive, giving an age standardised seroprevalence of 2.3 per cent (95% CI 1.8%–2.9%). This corresponds to approximately 433,000 people (95% CI 336,000 to 530,000) with HCV antibodies, in Australia, in 1998. Approximately 111,000 HCV notifications were reported from 1991 through 1998.

The age distribution for HCV seroprevalence and cumulative notification rate were similar, with the highest rates in the 20 to 49 year age groups and lowest rates in the age groups under 15 years and 50 years and older (Figure 1). However, the highest seroprevalence was in the 20 to 24 year age group, 5.3 per cent (95% CI 3.3%–8.1%) while the highest cumulative notification rate was in the 30 to 39 years age group, 1.1 per cent. There were more seropositive males than females overall (male: female ratio 1.8:1; 95% CI 1.3–3.0). This sex difference was greatest in the 25 to 29 years age group (Figure 2). The cumulative notification rate was also higher in males than in females (male:female ratio 1.7:1).
The prevalence estimate from the serosurvey of approximately 433,000 persons with HCV antibodies in Australia in 1998 is almost four fold greater than the 110,000 cumulative notifications reported from 1991 to the end of 1998 and more than double the 196,000 of people estimated to be seropositive in 1997 by mathematical modelling. Underestimates of either measure would result in an underestimate of population HCV prevalence. An under estimate of the proportion of HCV acquired through non-IDU modes of transmission (around 20% in the HCPWG estimates) would also produce an underestimate of population HCV prevalence. It is also possible that the serosurvey overestimates HCV prevalence.

Anonymous opportunistic testing of remanent sera has been shown to provide estimates of immunity comparable with a random population based survey of some vaccine preventable diseases. However, the lack of detailed information about participants in opportunistic serosurveys means that it is not possible to identify or control for various potential biases. In this serosurvey, the potential for selection bias was reduced by enrolling 87 per cent of major laboratories and including primarily ambulatory rather than hospitalised patients. The majority of Australian laboratories are located in major centres which may have resulted in selection bias. However, a comparison of Accessibility and Remoteness Index Australia scores for the population tested in the serosurvey and the Australian population showed that remote areas were not under-represented (data not shown). It is possible that people with chronic HCV were over sampled due to their potentially higher utilisation of health care services. The effect of this bias would be partially ameliorated by exclusion of sera from sexual health clinics but ideally sera from liver clinics should also have been excluded. Further, while this bias would result in an over estimation of overall prevalence, it should not distort the pattern of HCV seroprevalence by age or sex for HCV.

The low seroprevalence in persons over the age of 50 years in this study is consistent with findings from an opportunistic serosurvey in England and Wales and a population based random survey in the United States of America. In both of these surveys, seroprevalence was found to be associated with drug use. In contrast, a study from Italy in which seroprevalence was highest in older age groups, showed an association with medical interventions. The low levels of notification and seroprevalence in older age groups in Australia indicate that these age groups are not particularly subject to under notification and there is unlikely to be a hidden epidemic related to medical interventions in older Australians. A more robust estimate of HCV seroprevalence and conclusive evidence that IDU is the main source of infection in Australia, could be ascertained by undertaking a population based random sampled serosurvey in which risk factor information is col-
lected. However, such surveys are costly and can also be biased by non-participation especially by high-risk groups such as IDUs.

The impact on the health system of illness associated with chronic HCV infection over the next decade is likely to increase as those aged 20 to 50 in this study approach the duration of infection, 15–25 years, at which severe complications of hepatitis C arise.\textsuperscript{2,23} The projected high prevalence of such complications, makes the planning of health services to provide appropriate and accessible services and treatment, including antiviral therapy, imperative.

**Acknowledgements**

NCIRS is supported by the Australian Government Department of Health and Ageing, The NSW Department of Health and The Children’s Hospital at Westmead. NCHECR is supported by the Australian Government Department of Health and Ageing. We thank the staff of the 45 laboratories who provided the sera (http://immunise.health.gov.au/metadata/measeval.htm pages 8–9), laboratory staff at the ICPMR and the nurses at the RAHC Centre for Immunisation Research, Westmead, for their help in processing and testing the sera.

**References**


A multi-jurisdictional outbreak of hepatitis A related to a youth camp — implications for catering operations and mass gatherings.

Sally A Munnoch,1,2 Rosie H Ashbolt,1,3 David J Coleman,1 Nerissa Walton,4 Mary Y Beers-Deeble,2 Roscoe Taylor1

Abstract

In June 2003, Australian state and territory health departments were notified of an outbreak of Hepatitis A in people who had attended a five-day youth camp. Approximately 350 people attended the event in Central Australia between 24 and 28 April 2003. The public health investigation comprised of case identification, food handler interviews, an environmental health investigation of the campground and associated food premises, laboratory analysis of blood specimens and food/water samples, and an epidemiological study. Twenty-one cases fitted the case definition for the outbreak. A retrospective cohort study involving four states was conducted, with 213 people interviewed. Coleslaw and cordial were significantly associated with illness, however when the two exposures were adjusted for each other to account for confounding, only coleslaw remained significantly associated with illness (adjusted RR 2.5, 95% CI 1.09 – 5.77). The investigation highlighted a number of food hygiene and safety issues relating to the catering of mass gatherings. Implementation of food safety programs in these settings are likely to reduce the occurrence of such outbreaks. The recent proposal by Food Standards Australia New Zealand to mandate food safety programs for catering operations is supported. Commun Dis Intell 2004;28:521–527.

Keywords: Hepatitis A, camp, multi-jurisdictional, catering operations, mass gatherings

1. Public and Environmental Health Service, Department of Health and Human Services, Tasmania
2. Master of Applied Epidemiology Program, National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australian Capital Territory
3. OzFoodNet, Australian Government Department of Health and Ageing, Canberra, Australian Capital Territory
4. Northern Territory Department of Health and Community Services, Darwin, Northern Territory


References

